Clinical Trials
26 trialsNCT05011045 2026-05-20
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
M.D. Anderson Cancer Center
Recruiting
NCT07082270 2026-05-15
Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT05497804 2026-05-13
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
Mayo Clinic
Phase 2 Active not recruiting
NCT05981209 2026-05-13
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06622005 2026-04-21
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT03017820 2026-04-13
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT06048250 2026-04-07
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
City of Hope Medical Center
Phase 1 Recruiting
NCT07181941 2026-03-27
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT06232044 2026-03-25
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Alliance for Clinical Trials in Oncology
Phase 1/2 Recruiting
NCT04883242 2026-03-13
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
University of Washington
Phase 2 Active not recruiting
NCT07340853 2026-03-10
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Recruiting
NCT04764942 2026-02-25
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
Mayo Clinic
Phase 1/2 Active not recruiting
NCT06940297 2026-02-06
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 2 Recruiting
NCT05847569 2026-02-03
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
Mayo Clinic
Phase 2 Recruiting
NCT06627751 2026-01-12
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT06042725 2025-12-24
MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
Mayo Clinic
Phase 1 Recruiting
NCT05892393 2025-11-12
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
University of California, San Francisco
Phase 1 Recruiting
NCT06785415 2025-09-30
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Mayo Clinic
Phase 1/2 Recruiting
NCT06572605 2025-09-19
External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease
City of Hope Medical Center
Phase 1/2 Recruiting
NCT04493411 2025-07-24
Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI
University of Texas Southwestern Medical Center
Phase NA Terminated
NCT05950113 2024-05-01
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT03311828 2024-03-12
Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma
City of Hope Medical Center
Phase 1 Completed
NCT04409314 2023-08-21
Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy
University of California, San Francisco
Completed
NCT03506802 2020-07-24
NYSCT MM
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT00123773 2016-02-26
Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence
AHS Cancer Control Alberta
Phase 2 Completed
NCT01309334 2014-08-25
IMAJEM
Nantes University Hospital
Phase 3 Completed